To Evaluate the Efficacy, Safety, and Immunogenicity of Subcutaneous Eporon Versus Epoetin Alfa (Eprex)

Inclusion Criteria: * Glomerular Filtration Rate \<60 mL/min/1.73m2 (estimated by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation) * Hemoglobin (Hb) level in the range of ≥7 g/dL and \<10 g/dL at screening * Erythropoiesis Stimulating Agent (ESA) naïve subjects or previously treated subjects with ESA-free period of \>3 months (in case of pre-treatment with long-acting ESA such as pegylated epoetin, the long-acting ESA-free period of \>6 months) Exclusion Criteria: * Subjects who have received steady dialysis or subjects who are currently on dialysis * Subjects who have rapid progression of chronic renal failure (as per investigators' discretion; e.g., a GFR decrease of \>20% within 12 weeks prior to screening) * Subjects who have already undergone renal transplantation or who are scheduled for renal transplantation